Real-World Experience with Dolutegravir-Based Two-Drug Regimens

Table 2

Virologic response following DTG 2DR initiation according to viral load prior to DTG 2DR.

	Overall population (N = 278)
Suppressed at initiation of DTG 2DR (<50 copies/mL)	116 (41.7)
Suppressed, remained suppressed	110 (94.8)
Suppressed, became detectable	6 (5.2)
Nonsuppressed at initiation of DTG 2DR (≥50 copies/mL)	140 (50.3)
Detectable, became suppressed, remained suppressed	111 (79.3)
Detectable, remained detectable	22 (15.7)
Detectable, became suppressed, then rebounded	7 (5.0)
Virologic data not available	22 (7.9)

This population represents the number of patients who had data both at initiation and during follow-up. 2DR, 2-drug regimen; DTG, dolutegravir.